Data timelines which jump out from this announcement.
Azer-cel: Allogeneic CAR T cell therapy
- A preliminary early data update is anticipated in the second half of 2024
VAXINIA MAST Trial
- Bile tract cancer expansion trial opened and is expected to enroll approximately 10 patients; preliminary early data is expected in the second half 2024
OnCARlytics (CF33-CD19)
- Preliminary early combination data are expected in the fourth quarter of 2024
B Cell Immunotherapy: PD1-Vaxx
- Preliminary early data are expected in 2025
Good luck to all holders brave enough to have invested patient capital.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-23
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.002(3.45%) |
Mkt cap ! $409.9M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.8¢ | 5.6¢ | $358.0K | 6.227M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 2194926 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 541763 | 12 |
View Market Depth
| Last trade - 11.01am 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.7¢ |
Change
-0.002 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| 5.8¢ | 5.8¢ | 5.6¢ | 3038547 | ||
| Last updated 11.20am 14/06/2024 ? | |||||
| IMU (ASX) Chart |